Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931825 | 1.00 | HTR2C (0.38) | HTR2CSLC6A4MCHR1TACR1AOC3 | |
| SCHEMBL18327668 | 0.89 | HTR2C (0.41) | HTR2CSLC6A4MCHR1TACR1AOC3 | |
| SCHEMBL18327669 | 0.81 | RIPK1 (0.40) | HTR2CSLC6A4MCHR1TACR1CACNA1G | |
| SCHEMBL30931859 | 0.81 | HDAC1 (0.35) | CNR2APP | |
| SCHEMBL21553770 | 0.81 | HDAC1 (0.35) | CNR2APP | |
| SCHEMBL21551409 | 0.81 | TACR1 (0.45) | TACR1AOC3HSD17B1HSD17B2 | |
| SCHEMBL18325643 | 0.80 | HTR2C (0.39) | HTR2CSLC6A4TACR1CACNA1GCACNA1B | |
| SCHEMBL18327666 | 0.79 | CALM1 (0.46) | HTR2CSLC6A4TACR1CACNA1GCACNA1B | |
| SCHEMBL18325638 | 0.75 | HSD17B1 (0.38) | HTR2CSLC6A4TACR1CACNA1GCACNA1B | |
| SCHEMBL18325644 | 0.75 | HTR2C (0.36) | HTR2CSLC6A4MCHR1TACR1CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | HTR2C 4839/4885SLC6A4 4843/4885MCHR1 2272/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | HTR2C 4839/4885SLC6A4 4843/4885MCHR1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.